What is CureDuchenne?
CureDuchenne operates on a venture philanthropy model, dedicated to finding a cure for Duchenne muscular dystrophy (DMD). The organization channels capital into innovative research, facilitates early diagnosis, and champions improved treatment access for affected individuals. Beyond financial backing, CureDuchenne provides essential educational resources and robust support programs for families navigating the complexities of DMD, fostering vital connections with leading scientists, physical therapists, and fundraising specialists. Their commitment has already channeled over $50 million into research and care, marking substantial progress in the fight against this debilitating disease and contributing to the development of FDA-approved therapies.
How much funding has CureDuchenne raised?
CureDuchenne has raised a total of $785K across 2 funding rounds:
Debt
$350K
Debt
$435K
Debt (2020): $350K with participation from PPP
Debt (2021): $435K led by PPP
Key Investors in CureDuchenne
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for CureDuchenne?
The substantial enterprise-level capital infusion signifies CureDuchenne's advanced stage in its mission to combat Duchenne muscular dystrophy. This strategic investment is poised to accelerate the organization's research initiatives, expand its diagnostic capabilities, and broaden access to critical treatments. Future endeavors will likely focus on scaling successful programs, forging new research partnerships, and potentially influencing policy to further support the DMD community. The organization's sustained financial backing indicates a strong trajectory towards achieving its ultimate goal of a cure.
See full CureDuchenne company page
